<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A02B&quot;,&quot;href&quot;:&quot;atc/A02B.md&quot;},{&quot;label&quot;:&quot;nizatidine&quot;}]"></div>

# nizatidine

- **generic name:** nizatidine
- **ATC codes:** `A02BA04`
- **DrugBank:** [DB00585](https://go.drugbank.com/drugs/DB00585) · **PubChem:** [CID 3033637](https://pubchem.ncbi.nlm.nih.gov/compound/3033637)
- **molar mass:** 331.45 g/mol (C12H21N5O2S2) — DrugBank
- **groups:** approved

## About

Nizatidine is an H2-receptor antagonist used to treat acid-related conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn, indigestion, and Zollinger–Ellison syndrome. It is an approved medicine and remains in use for these acid-related disorders.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q1188290](https://www.wikidata.org/wiki/Q1188290) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-04 10:17 | 0:41 | 0/1/0 | 0/0/0 | 0/0/0 | 31,108/679 | ollama / qwen3.8:27b-mtp-q8_0 | 1 | 2/1 | 1/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: missing key parameters — none reported by this paper</sub><br><sub>route_to: `human_review`</sub> | [Abdel-Rahman_2004_reference](drugs/drug_nizatidine/Nizatidine_AbdelRahman2004_reference.md) | — | parent + metabolite (no model) | 0 | Abdel-Rahman SM et al., Developmental pharmacokinetics and phar…, Journal of pediatric gastro… (2004) | [10.1097/00005176-200404000-00015](https://doi.org/10.1097/00005176-200404000-00015) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=nizatidine) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` substrate | DrugBank actor |
| absorption | kidney | `ABCB1` substrate | DrugBank actor |
| absorption | liver | `ABCB1` substrate | DrugBank actor |
| absorption | placenta | `ABCB1` substrate | DrugBank actor |
| absorption | small intestine | `ABCB1` substrate | DrugBank actor |
| absorption | testis | `ABCB1` substrate | DrugBank actor |
| metabolism | blood | `BCHE` inhibitor | DrugBank actor |
| metabolism | liver | `BCHE` inhibitor | DrugBank actor |

<sub>Actors without a tissue in the table: HRH2 (target).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 46 matched, 42 returned
- **screened:** 2  ·  **relevant:** 2
- **records:** 1  ·  extracted 0  ·  needs_review 0  ·  rejected 1  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_11 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Sano_1991.pdf` | Sano H et al., Pharmacokinetics of nizatidine in dogs…, Xenobiotica; the fate of fo… (1991) | popPK | 10 | [10.3109/00498259109043200](https://doi.org/10.3109/00498259109043200) | [1796603](https://pubmed.ncbi.nlm.nih.gov/1796603) | The study reports quantitative PK parameters (Clp, Vd, bioavailability) for nizatidine in dogs and rats, but specific numeric values for clearance and volume are not explicitly listed in the provided text, only qualitative descriptions and one bioavailability value. |
| `Abdel-Rahman_2002.pdf` | Abdel-Rahman SM et al., Single-dose pharmacokinetics of nizatid…, Journal of clinical pharmac… (2002) | popPK | 9 | [10.1177/009127002401382687](https://doi.org/10.1177/009127002401382687) | [12362922](https://pubmed.ncbi.nlm.nih.gov/12362922) | The study reports quantitative PK parameters for nizatidine in children, but specific numeric values for clearance (CL/F) and volume (Vss/F) are described as being similar to adults rather than explicitly listed in the provided text. |
| `Lin_1991.pdf` | Lin JH, Pharmacokinetic and pharmacodynamic pro…, Clinical pharmacokinetics (1991) | pd | 5 | [10.2165/00003088-199120030-00004](https://doi.org/10.2165/00003088-199120030-00004) | [1673880](https://www.ncbi.nlm.nih.gov/pubmed/1673880) | metadata signals extractable PD data (IC50) |
| `Morrissey_2016.pdf` | Morrissey KM et al., The Effect of Nizatidine, a MATE2K Sele…, Clinical pharmacokinetics (2016) | pd | 5 | [10.1007/s40262-015-0332-9](https://doi.org/10.1007/s40262-015-0332-9) | [26507723](https://www.ncbi.nlm.nih.gov/pubmed/26507723) | metadata signals extractable PD data (IC50) |
| `van_1993.pdf` | van Zyl JM et al., Anti-oxidant properties of H2-receptor…, Biochemical pharmacology (1993) | pd | 5 | [10.1016/0006-2952(93)90218-l](https://doi.org/10.1016/0006-2952(93)90218-l) | [8101078](https://www.ncbi.nlm.nih.gov/pubmed/8101078) | metadata signals extractable PD data (IC50) |
| `Boom_1992.pdf` | Boom SP et al., Organic cation transport and cationic d…, The Journal of pharmacology… (1992) | pd | 4 | not captured | [1359105](https://www.ncbi.nlm.nih.gov/pubmed/1359105) | metadata signals extractable PD data (IC50) |
| `Boom_1993.pdf` | Boom SP et al., Cimetidine uptake and interactions with…, The Journal of pharmacology… (1993) | pd | 4 | not captured | [8263763](https://www.ncbi.nlm.nih.gov/pubmed/8263763) | metadata signals extractable PD data (IC50) |
| `Shimokawa_1996.pdf` | Shimokawa M et al., Neurotoxic convulsions induced by hista…, Toxicology and applied phar… (1996) | pd | 4 | [10.1006/taap.1996.0038](https://doi.org/10.1006/taap.1996.0038) | [8619239](https://www.ncbi.nlm.nih.gov/pubmed/8619239) | metadata signals extractable PD data (EC50) |
| `Ueki_1993.pdf` | Ueki S et al., Gastroprokinetic activity of nizatidine…, The Journal of pharmacology… (1993) | pd | 4 | not captured | [8093722](https://www.ncbi.nlm.nih.gov/pubmed/8093722) | metadata signals extractable PD data (IC50) |
| `Furuta_2001.pdf` | Furuta S et al., Inhibition of drug metabolism in human…, Xenobiotica; the fate of fo… (2001) | pgx | 7 | [10.1080/00498250110035615](https://doi.org/10.1080/00498250110035615) | [11334262](https://www.ncbi.nlm.nih.gov/pubmed/11334262) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Michalets_2000.pdf` | Michalets EL et al., Drug interactions with cisapride: clini…, Clinical pharmacokinetics (2000) | pgx | 7 | [10.2165/00003088-200039010-00004](https://doi.org/10.2165/00003088-200039010-00004) | [10926350](https://www.ncbi.nlm.nih.gov/pubmed/10926350) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |

<sub>queue written 2026-10-04T10:16:31.861055+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Abdel-Rahman_2002 | relevant | 9 | 2 | The study reports quantitative PK parameters for nizatidine in children, but specific numeric values for clearance (CL/F) and volume (Vss/F) are described as being similar to adults rather than explicitly listed in the provided text. |
| PD | Abdel-Rahman_2002 | not_relevant | 2 | 1 | The paper is a PK study that only qualitatively compares plasma concentrations to an EC50 value derived from external adult studies, without reporting any numeric PD parameters or concentration-effect data for the pediatric subjects. |
| PD | Abdel-Rahman_2004 | not_relevant | 3 | 1 | The paper reports PK parameters and qualitative changes in intragastric pH (mean/median/fraction of time) but does not provide a quantitative concentration-effect or dose-response model with numeric PD parameters (e.g., EC50, Emax) for nizatidine. |
| popPK | Blum_2003 | relevant | 8 | 2 | The study reports PK parameters for nizatidine, but the evidence only provides relative changes (e.g., Cmax reduction, bioavailability) and lacks specific absolute numeric values for clearance, volume, or half-life. |
| PD | Blum_2003 | not_relevant | 3 | 2 | The paper reports PK parameters and qualitative/summary PD metrics (pH AUC, % time pH &gt; 3.0/4.0) but does not provide a concentration-effect curve, Emax/EC50, or any numeric PD model parameters. |
| popPK | Boom_1992 | irrelevant | 0 | 0 | no_text gate: only 109 chars of text extracted (&lt; 400) |
| PD | Boom_1992 | not_relevant | 0 | 0 | The paper focuses on organic cation transport mechanisms in rat proximal tubular cells and does not report pharmacodynamic or exposure-response relationships for nizatidine. |
| popPK | Boom_1993 | irrelevant | 0 | 0 | no_text gate: only 108 chars of text extracted (&lt; 400) |
| PD | Boom_1993 | not_relevant | 0 | 0 | The paper focuses on cimetidine uptake and interactions in rat proximal tubular cells, not nizatidine pharmacodynamics or exposure-response relationships. |
| popPK | Dahan_2009 | irrelevant | 1 | 0 | The study is an in-vitro mechanistic investigation of intestinal efflux transport in Caco-2 cells, not a pharmacokinetic study reporting quantitative disposition parameters (CL, V, t1/2) for nizatidine. |
| PD | Dahan_2009 | not_relevant | 0 | 0 | The paper characterizes intestinal transport kinetics (P-gp efflux) in Caco-2 cells, not pharmacodynamic exposure-response or dose-response relationships for the drug's therapeutic effect. |
| popPK | Dammann_1986 | irrelevant | 0 | 0 | The study reports pharmacodynamic outcomes (acid suppression) rather than quantitative pharmacokinetic parameters (CL, V, ka, etc.) for nizatidine. |
| popPK | Dammann_1987 | irrelevant | 0 | 0 | The study reports pharmacodynamic acid suppression data, not pharmacokinetic disposition parameters for nizatidine. |
| popPK | Danziger_1989 | relevant | 8 | 0 | The study is a PK/PD trial for nizatidine, but the specific numeric PK parameter values (CL, V, etc.) are not present in the provided abstract text. |
| popPK | Dyck_1987 | irrelevant | 0 | 0 | The paper is a clinical efficacy trial for duodenal ulcer healing and does not report any pharmacokinetic parameters for nizatidine. |
| PD | Dyck_1987 | not_relevant | 4 | 2 | The paper describes a dose-response clinical trial but the provided text only contains qualitative comparisons of healing rates without specific numeric effect values or concentration data to derive PD parameters. |
| PGx | Furuta_2001 | not_relevant | 0 | 0 | The paper investigates in vitro CYP inhibition by nizatidine and does not report any pharmacogenomic effects (gene variants) on PK or PD parameters. |
| popPK | Gladziwa_1993 | irrelevant | 2 | 0 | The text is a qualitative review summarizing general trends in renal insufficiency without providing specific quantitative PK parameter values (e.g., CL, V, t1/2) for nizatidine. |
| PD | Gladziwa_1993 | not_relevant | 1 | 0 | The text is a qualitative review summarizing PK changes and stating that acid inhibition is prolonged, but it provides no numeric PD parameters, dose-response curves, or quantitative exposure-response data. |
| popPK | Kawakami_1997 | irrelevant | 0 | 0 | The provided evidence contains only software metadata and no scientific content or pharmacokinetic data for nizatidine. |
| PD | Kawakami_1997 | not_relevant | 0 | 0 | The provided text is metadata for the GROBID software and does not contain any pharmacological data, study results, or PD parameters for nizatidine. |
| popPK | Lauritsen_1990 | irrelevant | 2 | 0 | The paper is a review article that discusses nizatidine only as a class representative without providing original quantitative pharmacokinetic parameter values. |
| PD | Lauritsen_1990 | not_relevant | 2 | 0 | The text is an abstract for a general review of clinical pharmacokinetics in gastrointestinal diseases and mentions PK/PD relationships only qualitatively without providing specific numeric PD parameters or models for nizatidine. |
| popPK | Lazzaroni_1989 | irrelevant | 0 | 0 | The study is a pharmacodynamic comparison of acid secretion inhibition and does not report any pharmacokinetic parameters for nizatidine. |
| PD | Lazzaroni_1989 | not_relevant | 3 | 2 | The study reports qualitative comparisons of acid inhibition percentages between nizatidine and ranitidine but does not provide a concentration-effect relationship, dose-response curve, or numeric PD parameters (e.g., Emax, EC50) for nizatidine. |
| popPK | Lin_1986 | irrelevant | 0 | 0 | The paper describes pharmacodynamic effects (receptor affinity, acid output, cytoprotection) and does not report any pharmacokinetic parameters such as clearance, volume, or half-life for nizatidine. |
| popPK | Lin_1991 | irrelevant | 0 | 0 | no_text gate: only 159 chars of text extracted (&lt; 400) |
| popPK | Michalets_2000 | irrelevant | 0 | 0 | no_text gate: only 55 chars of text extracted (&lt; 400) |
| PD | Michalets_2000 | not_relevant | 0 | 0 | The paper discusses drug interactions with cisapride and does not report any pharmacodynamic or exposure-response analysis for nizatidine. |
| PGx | Michalets_2000 | not_relevant | 0 | 0 | The paper discusses drug-drug interactions with cisapride, not pharmacogenomic effects on nizatidine. |
| popPK | Mimaki_2001 | irrelevant | 0 | 0 | The study investigates the pharmacodynamic mechanism of nizatidine (bicarbonate secretion and AChE inhibition) in rats and does not report any pharmacokinetic parameters. |
| PGx | Moody_2013 | not_relevant | 0 | 0 | The paper reports in vitro inhibition of methadone and oxycodone metabolism by nizatidine, not a pharmacogenomic effect on nizatidine's own PK/PD parameters. |
| popPK | Morrissey_2016 | irrelevant | 0 | 0 | no_text gate: only 135 chars of text extracted (&lt; 400) |
| PD | Morrissey_2016 | not_relevant | 0 | 0 | The provided text is only the title of the paper and does not contain the full text, results, or any numeric PD parameters or exposure-response data. |
| popPK | Price_1988 | irrelevant | 1 | 0 | The paper is a preliminary review of pharmacodynamic and therapeutic properties without reporting specific quantitative pharmacokinetic parameter values (e.g., CL, V, t1/2) for nizatidine. |
| PD | Price_1988 | not_relevant | 2 | 0 | The text is a qualitative review summarizing therapeutic efficacy and general pharmacodynamic properties without providing specific numeric PD parameters (e.g., EC50, Emax) or concentration-effect data. |
| popPK | Rahman_2020 | irrelevant | 0 | 0 | The study is an in-vitro spectroscopic and computational analysis of protein binding, not a pharmacokinetic study reporting quantitative disposition parameters like clearance or volume. |
| PD | Rahman_2020 | not_relevant | 0 | 0 | The paper investigates the molecular binding interaction between nizatidine and bovine serum albumin (BSA) using spectroscopic and computational methods, not a pharmacodynamic exposure-response or dose-response relationship in a biological system. |
| popPK | Roberts_1986 | irrelevant | 1 | 0 | The study is an in-vitro perfused rat liver experiment where nizatidine is a co-administered agent affecting the extraction of lidocaine, not a study reporting nizatidine's own pharmacokinetic parameters. |
| popPK | Sano_1991 | relevant | 10 | 2 | The study reports quantitative PK parameters (Clp, Vd, bioavailability) for nizatidine in dogs and rats, but specific numeric values for clearance and volume are not explicitly listed in the provided text, only qualitative descriptions and one bioavailability value. |
| popPK | Savarino_1990 | irrelevant | 0 | 0 | The study is a pharmacodynamic assessment of gastric pH suppression and does not report any pharmacokinetic parameters for nizatidine. |
| PD | Savarino_1990 | not_relevant | 3 | 2 | The paper reports comparative pharmacodynamic effects (gastric pH) of nizatidine versus other drugs but does not provide a concentration-effect or dose-response model with numeric PD parameters (e.g., Emax, EC50) for nizatidine. |
| popPK | Sharma_1998 | irrelevant | 0 | 0 | The paper is a review of pharmacodynamic indirect response models and uses nizatidine only as a clinical example for pharmacodynamics, without reporting quantitative pharmacokinetic parameters for the drug. |
| PD | Sharma_1998 | not_relevant | 3 | 0 | The paper is a review of indirect response models; while it mentions nizatidine as an application example, the provided text does not contain specific numeric PD parameters (e.g., IC50, Emax) for nizatidine. |
| popPK | Shimokawa_1996 | irrelevant | 0 | 0 | no_text gate: only 75 chars of text extracted (&lt; 400) |
| PD | Shimokawa_1996 | not_relevant | 0 | 0 | The paper describes neurotoxic convulsions in mice but does not report a pharmacodynamic exposure-response or dose-response relationship for nizatidine with numeric PD parameters. |
| popPK | Staines_2021 | irrelevant | 0 | 0 | The paper is an in-vitro mechanistic study on bone mineralization where nizatidine is used only as a negative control/comparator, and no pharmacokinetic parameters are reported. |
| PD | Staines_2021 | not_relevant | 0 | 0 | The paper explicitly states that nizatidine had no inhibitory effects on PHOSPHO1 activity and does not report any numeric PD parameters or dose-response relationship for nizatidine. |
| popPK | Takeuchi_2000 | irrelevant | 0 | 0 | The study investigates the pharmacodynamic mechanism of nizatidine (stimulation of duodenal bicarbonate secretion via anti-cholinesterase activity) and does not report any pharmacokinetic parameters such as clearance, volume, or half-life. |
| popPK | Ueki_1993 | irrelevant | 0 | 0 | no_text gate: only 124 chars of text extracted (&lt; 400) |
| PD | Ueki_1993 | not_relevant | 0 | 0 | The paper focuses on the gastroprokinetic activity and mechanism of action of nizatidine, not on pharmacodynamic exposure-response or dose-response modeling with numeric PD parameters. |
| popPK | Vargas_1988 | irrelevant | 2 | 0 | The study focuses on pharmacodynamics (acid secretion) and only qualitatively mentions a similar pharmacokinetic profile without providing any quantitative PK parameters (CL, V, t1/2, etc.) for nizatidine. |
| popPK | Walt_1989 | irrelevant | 0 | 0 | The paper is a clinical review discussing the therapeutic roles of H2-antagonists and does not report any quantitative pharmacokinetic parameters for nizatidine. |
| PD | Walt_1989 | not_relevant | 1 | 0 | The text is a qualitative review discussing the clinical importance and relative potency of H2-antagonists without providing any numeric PD parameters, concentration-effect curves, or specific exposure-response data for nizatidine. |
| popPK | van_1993 | irrelevant | 0 | 0 | no_text gate: only 168 chars of text extracted (&lt; 400) |
| PD | van_1993 | not_relevant | 0 | 0 | The paper investigates the antioxidant properties of H2-receptor antagonists in an in vitro chemical system, not the pharmacodynamic exposure-response relationship of nizatidine in a biological or clinical context. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-18 06:23 UTC</sub>
